市場調查報告書

低纖維蛋白原血症 - 流行病學預測 - 2030年

Hypofibrinogenemia - Epidemiology Forecast - 2030

出版商 DelveInsight Business Research LLP 商品編碼 955321
出版日期 內容資訊 英文 100 Pages
商品交期: 最快1-2個工作天內
價格
低纖維蛋白原血症 - 流行病學預測 - 2030年 Hypofibrinogenemia - Epidemiology Forecast - 2030
出版日期: 2020年08月01日內容資訊: 英文 100 Pages
簡介

主要7個國家的低纖維蛋白原血症的有病例,2017年估計有11,084案例。根據估計低纖維蛋白原血症的患病人數最多的是美國。在歐洲5個國家中,德國患病人數最多。另一方面,西班牙的患病人數最少,2017年是493個案例。

本報告提供低纖維蛋白原血症的相關調查,流行病學,疾病的概要,及主要7個市場 (美國,德國,法國,義大利,西班牙,英國,日本) 的市場趨勢與預測,未滿足需求等相關分析。

目錄

第1章 主要考察

第2章 低纖維蛋白原血症:流行病學概要

  • 低纖維蛋白原血症的患者佔有率(%)分佈
  • 低纖維蛋白原血症的患者佔有率(%)分佈預測

第3章 摘要整理

第4章 組織

第5章 疾病概要:低纖維蛋白原血症

  • 簡介
  • 分類
  • 徵兆與症狀
  • 病因
  • 診斷
    • 鑑別診斷
    • 產前診斷

第6章 流行病學和患者人口

  • 主要調查結果
  • 低纖維蛋白原血症的主要7個市場的病例

第7章 低纖維蛋白原血症的流行病學:各國

  • 假設和根據
  • KOL的見解:流行病學
  • 美國
    • 美國的低纖維蛋白原血症的病例
    • 美國的低纖維蛋白原血症的各類型病例
    • 美國的後天性低纖維蛋白原血症的病例
  • 德國
  • 法國
  • 義大利
  • 西班牙
  • 英國
  • 日本

第8章 目前治療慣行

第9章 未滿足需求

第10章 SWOT分析

第11章 參考文件

第12章 附錄

  • 報告調查手法

章13:DelveInsight的服務內容

第14章 免責聲明

第15章:關於DelveInsight

目錄
Product Code: DIEI1015

DelveInsight's 'Hypofibrinogenemia- Epidemiology Forecast-2030' report delivers an in-depth understanding of the Hypofibrinogenemia, historical and forecasted epidemiology in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.

Hypofibrinogenemia Disease Understanding

Fibrinogen disorders are a set of hereditary or acquired abnormalities generally considered as rare conditions that are majorly classified as either qualitative (type II) or quantitative (type I). Qualitative fibrinogen disorder is a functional disorder that includes dysfibrinogenemia and hypodysfibrinogenemia.

Quantitative fibrinogen disorders, on the other hand, are characterized by the low amount of fibrinogen in the circulation and are further classified as hypofibrinogenemia, characterized by low fibrinogen levels. Generally, normal plasma fibrinogen levels are considered to range from 1.5 to 4.5 g/L; however, in hypofibrinogenaemia, plasma fibrinogen is reduced and characterized by fibrinogen levels lower than 1.5 g/L. In contrast, afibrinogenemia is an autosomal recessive disease, characterized by the complete deficiency of fibrinogen.

It is broadly classified into two types, i.e., Congenital Hypofibrinogenemia and Acquired Hypofibrinogenemia. Congenital fibrinogen disorders are caused by genetic variants occurring within all three fibrinogen genes. However, each gene (FGA, FGB, FGG) differently shows specific variants, wherein "nonsense" variants are mostly found within FGA, while FGG variants are prevalently responsible for missense changes.

In congenital hypofibrinogenemia, genes responsible for producing fibrinogen (a critical blood clotting factor) are unable to make a functional fibrinogen glycoprotein because of an inherited mutation. In contrast, acquired hypofibrinogenemia can result from either severe hepatic disease or disseminated intravascular coagulation (DIC), cardiac surgery, etc.

Hypofibrinogenemia Epidemiology

The Hypofibrinogenemia epidemiology division provides insights about the historical and current patient pool along with the forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

The disease epidemiology covered in the report provides historical as well as forecasted Hypofibrinogenemia epidemiology segmented as the Total Cases of Hypofibrinogenemia, Type-Specific Cases of Hypofibrinogenemia (as congenital and acquired), and Acquired Hypofibrinogenemia cases. The report includes the Prevalent scenario of Hypofibrinogenemia symptoms in 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2017 to 2030.

Country Wise- Hypofibrinogenemia Epidemiology

The epidemiology segment also provides the Hypofibrinogenemia epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.

The total prevalent population of Hypofibrinogenemia Associated in 7MM countries estimated to be 11,084 cases in 2017.

  • As per the estimates, the United States has the highest Prevalent population of Hypofibrinogenemia
  • Among the EU5 countries, Germany had the highest prevalent population of Hypofibrinogenemia. On the other hand, Spain had the lowest prevalent population with 493 cases in 2017.

Scope of the Report:

  • Hypofibrinogenemia report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
  • Hypofibrinogenemia Epidemiology Report and Model provide an overview of the risk factors and global trends of Hypofibrinogenemia in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan)
  • The report provides insight into the historical and forecasted patient pool of Hypofibrinogenemia in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) and Japan
  • The report helps to recognize the growth opportunities in the 7MM concerning the patient population
  • The report assesses the disease risk and burden and highlights the unmet needs of Hypofibrinogenemia
  • The report provides the segmentation of the Hypofibrinogenemia epidemiology by Prevalent Cases of Hypofibrinogenemia in 7MM
  • The report provides the segmentation of the Hypofibrinogenemia epidemiology by Type -specific Prevalent Cases of Hypofibrinogenemia in 7MM

Report Highlights:

  • 11-Year Forecast of Hypofibrinogenemia epidemiology
  • 7MM Coverage
  • Total Prevalent Cases of Hypofibrinogenemia
  • Prevalent Cases according to segmentation: Type-specific Prevalence of Hypofibrinogenemia, Acquired Hypofibrinogenemia cases

KOL- Views

We interview KOLs, and SME's opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps to understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.

Key Questions Answered

  • What will be the growth opportunities in the 7MM concerning the patient population about Hypofibrinogenemia?
  • What are the key findings of Hypofibrinogenemia epidemiology across 7MM and which country will have the highest number of patients during the forecast period (2017-2030)?
  • What would be the total number of patients of Hypofibrinogenemia across the 7MM during the forecast period (2017-2030)?
  • Among the EU5 countries, which country will have the highest number of patients during the forecast period (2017-2030)?
  • At what CAGR the patient population is expected to grow in 7MM during the forecast period (2017-2030)?
  • What are the disease risk, burden, and unmet needs of Hypofibrinogenemia?
  • What are the currently available treatments for Hypofibrinogenemia?

Reasons to buy:

The Hypofibrinogenemia Epidemiology report will allow the user to -

  • Develop business strategies by understanding the trends shaping and driving the global Hypofibrinogenemia market
  • Quantify patient populations in the global Hypofibrinogenemia market to improve product design, pricing, and launch plans
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Hypofibrinogenemia therapeutics in each of the markets covered
  • Understand the magnitude of Hypofibrinogenemia population by its Prevalence cases
  • Understand the magnitude of Hypofibrinogenemia population by its Type-specific cases
  • The Hypofibrinogenemia epidemiology report and model were written and developed by Masters and Ph.D. level epidemiologists
  • The Hypofibrinogenemia Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources

Key Assessments

  • Patient Segmentation
  • Disease Risk and Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population

Geographies Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017-2030

The frequency of congenital fibrinogen disorders in the general population is very low. A North American Registry of Rare Bleeding Disorders has been successful in collecting valuable information on inherited fibrinogen disorders and other rare bleeding disorders. Among all the reported fibrinogen disorders in this registry, afibrinogenemia accounted for 24% of cases, hypofibrinogenemia accounted for 38%, and dysfibrinogenemia accounted for 38%.

Table of Contents

1. Key Insights

2. Hypofibrinogenemia: Epidemiology Overview at a Glance

  • 2.1. Patient Share (%) Distribution of Hypofibrinogenemia in 2017
  • 2.2. Patient Share (%) Distribution of Hypofibrinogenemia in 2030

3. Executive summary

4. Organizations

5. Disease Overview: Hypofibrinogenemia

  • 5.1. Introduction
  • 5.2. Classification
  • 5.3. Signs and Symptoms
  • 5.4. Pathogenesis
  • 5.5. Diagnosis
    • 5.5.1. Differential Diagnosis
    • 5.5.2. Prenatal Diagnosis

6. Epidemiology and Patient Population

  • 6.1. Key Findings
  • 6.2. 7MM Total cases of Hypofibrinogenemia

7. Country Wise-Epidemiology of Hypofibrinogenemia

  • 7.1. Assumptions and Rationale
  • 7.2. KOL Views: Epidemiology
  • 7.3. United States
    • 7.3.1. Total Cases of Hypofibrinogenemia in the United States
    • 7.3.2. Type-Specific Cases of Hypofibrinogenemia in the US
    • 7.3.3. Acquired Hypofibrinogenemia cases in the US
  • 7.4. Germany
    • 7.4.1. Total Cases of Hypofibrinogenemia in Germany
    • 7.4.2. Type-Specific Cases of Hypofibrinogenemia in Germany
    • 7.4.3. Acquired Hypofibrinogenemia cases in Germany
  • 7.5. France
    • 7.5.1. Total Cases of Hypofibrinogenemia in France
    • 7.5.2. Type-Specific Cases of Hypofibrinogenemia in France
    • 7.5.3. Acquired Hypofibrinogenemia cases in France
  • 7.6. Italy
    • 7.6.1. Total Cases of Hypofibrinogenemia in Italy
    • 7.6.2. Type-Specific Cases of Hypofibrinogenemia in Italy
    • 7.6.3. Acquired Hypofibrinogenemia cases in Italy
  • 7.7. Spain
    • 7.7.1. Total Cases of Hypofibrinogenemia in Spain
    • 7.7.2. Type-Specific Cases of Hypofibrinogenemia in Spain
    • 7.7.3. Acquired Hypofibrinogenemia cases in the Spain
  • 7.8. United Kingdom
    • 7.8.1. Total Cases of Hypofibrinogenemia in the UK
    • 7.8.2. Type-Specific Cases of Hypofibrinogenemia in the UK
    • 7.8.3. Acquired Hypofibrinogenemia cases in the UK
  • 7.9. Japan
    • 7.9.1. Total Cases of Hypofibrinogenemia in Japan
    • 7.9.2. Type-Specific Cases of Hypofibrinogenemia in Japan
    • 7.9.3. Acquired Hypofibrinogenemia cases in Japan

8. Current Treatment Practices

9. Unmet needs

10. SWOT Analysis

11. Bibliography

12. Appendix

  • 12.1. Report Methodology

13. DelveInsight Capabilities

14. Disclaimer

15. About DelveInsight

List of Tables

  • Table 1: Causes of Acquired Hypofibrinogenemia
  • Table 2: Classification of Hypofibrinogenemia based on levels of functional fibrinogen
  • Figure 3: Schematic structure of the fibrinogen molecule
  • Figure 4: Schematic structure of the fibrinogen molecule
  • Figure 5: Schematic conversion of fibrinogen molecule to active fibrin
  • Table 6: Common mutations associated with hypofibrinogenemia
  • Table 7: Hypofibrinogenemia Mutations associated with liver damage
  • Table 8: Laboratory Assays in congenital fibrinogen deficiencies
  • Table 9: Laboratory diagnosis results for hypofibrinogenemia.
  • Table 10: Total cases of Hypofibrinogenemia in USD Million (2017-2030)
  • Table 11: Total Cases of Hypofibrinogenemia in the US (2017-2030)
  • Table 12: Type-specific Cases of Hypofibrinogenemia in the US (2017-2030)
  • Table 13: Acquired Hypofibrinogenemia cases in the US (2017-2030)
  • Table 14: Total Cases of Hypofibrinogenemia in Germany (2017-2030)
  • Table 15: Type-specific Cases of Hypofibrinogenemia in Germany (2017-2030)
  • Table 16: Acquired Hypofibrinogenemia cases in Germany (2017-2030)
  • Table 17: Total Cases of Hypofibrinogenemia in France (2017-2030)
  • Table 18: Type-specific Cases of Hypofibrinogenemia in France (2017-2030)
  • Table 19: Acquired Hypofibrinogenemia cases in France (2017-2030)
  • Table 20: Total Cases of Hypofibrinogenemia in Italy (2017-2030)
  • Table 21: Type-specific Cases of Hypofibrinogenemia in Italy (2017-2030)
  • Table 22: Acquired Hypofibrinogenemia cases in Italy (2017-2030)
  • Table 23: Total Cases of Hypofibrinogenemia in Spain (2017-2030)
  • Table 24: Type-specific Cases of Hypofibrinogenemia in Spain (2017-2030)
  • Table 25: Acquired Hypofibrinogenemia cases in Spain (2017-2030)
  • Table 26: Total Cases of Hypofibrinogenemia in the UK (2017-2030)
  • Table 27: Type-specific Cases of Hypofibrinogenemia in the UK (2017-2030)
  • Table 28: Acquired Hypofibrinogenemia cases in the UK (2017-2030)
  • Table 29: Total Cases of Hypofibrinogenemia in Japan (2017-2030)
  • Table 30: Type-specific Cases of Hypofibrinogenemia in Japan (2017-2030)
  • Table 31: Acquired Hypofibrinogenemia cases in Japan (2017-2030)

List of Figures

  • Figure 1: Total Cases of Hypofibrinogenemia in 7MM (2017-2030)
  • Figure 2: Total Cases of Hypofibrinogenemia in the United States (2017-2030)
  • Figure 3: Type-specific Cases of Hypofibrinogenemia in the US (2017-2030)
  • Figure 4: Acquired Hypofibrinogenemia cases in the US (2017-2030)
  • Figure 5: Total Cases of Hypofibrinogenemia in Germany (2017-2030)
  • Figure 6: Type-specific Cases of Hypofibrinogenemia in Germany (2017-2030)
  • Figure 7: Acquired Hypofibrinogenemia cases in Germany (2017-2030)
  • Figure 8: Total Cases of Hypofibrinogenemia in France (2017-2030)
  • Figure 9: Type-specific Cases of Hypofibrinogenemia in France (2017-2030)
  • Figure 10: Acquired Hypofibrinogenemia cases in France (2017-2030)
  • Figure 11: Total Cases of Hypofibrinogenemia in Italy (2017-2030)
  • Figure 12: Type-specific Cases of Hypofibrinogenemia in Italy (2017-2030)
  • Figure 13: Acquired Hypofibrinogenemia cases in Italy (2017-2030)
  • Figure 14: Total Cases of Hypofibrinogenemia in Spain (2017-2030)
  • Figure 15: Type-specific Diagnosed Prevalent Cases of Hypofibrinogenemia in Spain (2017-2030)
  • Figure 16: Acquired Hypofibrinogenemia cases in Spain (2017-2030)
  • Figure 17: Total Cases of Hypofibrinogenemia in the UK (2017-2030)
  • Figure 18: Type-specific Cases of Hypofibrinogenemia in the UK (2017-2030)
  • Figure 19: Acquired Hypofibrinogenemia cases in the UK (2017-2030)
  • Figure 20: Total Cases of Hypofibrinogenemia in Japan (2017-2030)
  • Figure 21: Type-specific Cases of Hypofibrinogenemia in Japan (2017-2030)
  • Figure 22: Acquired Hypofibrinogenemia cases in Japan (2017-2030)